Therefore, application of combination of BM-06 with sorafenib would be an ideal option in treatment of patients with cancers because such a combination can simultaneously block signaling through the sorafenib MEK or synergize TLR3 signaling. The gene discussed is MAP2K7; the disease is cancer.